Search by Drug Name or NDC
NDC 24510-0115-20 XTAMPZA 13.5 mg/1 Details
XTAMPZA 13.5 mg/1
XTAMPZA is a ORAL CAPSULE, EXTENDED RELEASE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Collegium Pharmaceutical, Inc.. The primary component is OXYCODONE.
MedlinePlus Drug Summary
Oxycodone is used to relieve moderate to severe pain. Oxycodone extended-release tablets and extended-release capsules are used to relieve severe pain in people who are expected to need pain medication around the clock for a long time and who cannot be treated with other medications. Oxycodone extended-release tablets and extended-release capsules should not be used to treat pain that can be controlled by medication that is taken as needed. Oxycodone extended-release tablets, extended-release capsules, and concentrated solution should only be used to treat people who are tolerant (used to the effects of the medication) to opioid medications because they have taken this type of medication for at least one week. Oxycodone is in a class of medications called opiate (narcotic) analgesics. It works by changing the way the brain and nervous system respond to pain. Oxycodone is also available in combination with acetaminophen (Oxycet, Percocet, Roxicet, Xartemis XR, others); aspirin (Percodan); and ibuprofen. This monograph only includes information about the use of oxycodone alone. If you are taking an oxycodone combination product, be sure to read information about all the ingredients in the product you are taking and ask your doctor or pharmacist for more information.
Related Packages: 24510-0115-20Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Oxycodone
Product Information
| NDC | 24510-0115 |
|---|---|
| Product ID | 24510-115_748773b1-947f-437e-a875-a05076d8d56b |
| Associated GPIs | 6510007500A315 |
| GCN Sequence Number | 076032 |
| GCN Sequence Number Description | oxycodone myristate CAP SPR 12 13.5 MG ORAL |
| HIC3 | H3A |
| HIC3 Description | OPIOID ANALGESICS |
| GCN | 41273 |
| HICL Sequence Number | 043376 |
| HICL Sequence Number Description | OXYCODONE MYRISTATE |
| Brand/Generic | Brand |
| Proprietary Name | XTAMPZA |
| Proprietary Name Suffix | ER |
| Non-Proprietary Name | OXYCODONE |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | CAPSULE, EXTENDED RELEASE |
| Route | ORAL |
| Active Ingredient Strength | 13.5 |
| Active Ingredient Units | mg/1 |
| Substance Name | OXYCODONE |
| Labeler Name | Collegium Pharmaceutical, Inc. |
| Pharmaceutical Class | Full Opioid Agonists [MoA], Opioid Agonist [EPC] |
| DEA Schedule | CII |
| Marketing Category | NDA |
| Application Number | NDA208090 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 24510-0115-20 (24510011520)
| NDC Package Code | 24510-115-20 |
|---|---|
| Billing NDC | 24510011520 |
| Package | 20 CAPSULE, EXTENDED RELEASE in 1 BLISTER PACK (24510-115-20) |
| Marketing Start Date | 2016-05-10 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |